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Abstract 
Background:  Inhabitants of Appalachian Kentucky are encumbered by tremendous health 
disparities, exhibit high rates of prescription drug abuse, and often co-present with psychiatric 
disorders.  Compared to opioids, little research has focused on the nonmedical use of 
benzodiazepines.    
Objective: To examine the association between nonmedical benzodiazepine use and major 
depressive disorder (MDD), generalized anxiety disorder (GAD), post-traumatic stress disorder 
(PTSD), and anti-social personality disorder (ASPD) in a population of opioid drug abusers.  
Methods:  Data for this cross-sectional study was obtained from the Social Networks among 
Appalachian People (SNAP) study.  Contingency tables analysis and the X
2
statistic were used to 
examine the association between past 30 day benzodiazepine (i.e., alprazolam, clonazepam, 
diazepam) use and psychiatric diagnoses.  The independent correlates of recent benzodiazepine 
use were determined using multiple logistic regression. 
Results:  503 participants were included in this analysis. All reported a lifetime history of opioid 
drug abuse and 98% (n=493) reported use within the past 30 days.  71% (n=355) reported past 
30 day benzodiazepine (i.e., alprazolam, clonazepam, or diazepam) use.  The presence of MDD 
(Odds Ratio [OR]: 1.9, 95% Confidence Interval [CI]: 1.2-3.0) or GAD (OR: 1.9, 95% CI: 1.2-
3.0) were significantly (p<0.05) associated with recent benzodiazepine use.  Other variables 
associated with benzodiazepine use were: illicit methadone use (Adjusted OR [AOR]: 2.94, 95% 
CI: 1.9-4.56, marijuana use(AOR: 2.57, 95% CI: 1.64-4.01), oxycodone use (AOR: 2.52, 95% 
CI: 1.6-3.97), GAD (AOR: 1.67, 95% CI: 1.01-2.77), poor/fair health (AOR: 1.65, 2.6), and 
years living in eastern Kentucky (AOR: 1.03, 95% CI: 1.0-1.1).  
Discussion: The results show a strong association between nonmedical benzodiazepine use and 
psychiatric disorders (i.e., MDD, GAD).  A lack of accessible mental healthcare providers may 
be a contributing factor to the high rates of nonmedical benzodiazepine use found in this study.  
Longitudinal studies are needed to examine the effect of prescription drug monitoring programs 
on benzodiazepine abuse. 
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1. Introduction 
Prescription drugs are the second most abused class of drugs in the United States.  The 
prevalence of prescription drug abuse has rapidly increased over the past decade with one in 
every five Americans over the age of 12 now being able to report using a prescription drug for a 
nonmedical purpose at least once in their lifetime.
1
  This epidemic has taken a toll not only on 
individual abusers, but the entire country.  Prescription opioids are the most common class of 
medications abused with their total yearly economic cost of nonmedical use being more than $50 
billion.
2
 Accordingly, the majority of prescription drug abuse research has been focused on 
opioids.  However, other prescription medications, such as benzodiazepines, are also frequently 
abused.   
Benzodiazepines are Schedule IV medications and exert their pharmacologic effects by binding 
to receptors in the brain, which in turn increase the effects of gamma-aminobutyric acid 
(GABA).  GABA is an inhibitory neurotransmitter that produces a calming and sedating effect.  
Benzodiazepines are approved for the short term treatment of anxiety but are also frequently 
prescribed long term and for uses other than their labeled indications.   
Between 1998 and 2007, the number of alprazolam and clonazepam prescriptions dispensed 
through outpatient retail pharmacies increased 71% and 114% respectively.
3
  One substantial 
issue in relation to prescription drug abuse is the treatment of patients with chronic pain.  A 
common “drug cocktail” prescribed to patients with chronic pain consists of an opioid, 
benzodiazepine, and muscle relaxer.  This combination of drugs is frequently prescribed to 
patients suffering from chronic pain despite a lack of proven clinical benefit.  The prevalence of 
benzodiazepine prescribing has been increasing at a rate comparable to that of opioids
4
, but 
4 
 
research investigating the factors associated with abuse and nonmedical use of benzodiazepines 
is lacking. 
Residents of the Appalachian region of Kentucky suffer from severe health disparities and have 
rates of prescription drug abuse and mental health disorders that exceed national averages.
5
  The 
self-medication hypothesis of addictive disorders, first described by Dr. Edward Khantzian, may 
explain this relationship.
6 
 This hypothesis suggests that individuals with psychiatric disorders 
crave certain drugs of abuse because of the specific pharmacologic properties of the drug.  Thus, 
the primary objective of this study was to determine if a relationship exists between nonmedical 
benzodiazepine use and DMS-IV psychiatric disorders such as: major depressive disorder 
(MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) in a 
population of opioid drug abusers residing in Appalachian Kentucky.  The hypothesis being that 
drug abusers with an underlying psychiatric illness may use benzodiazepines to self-medicate 
comorbid conditions.  A secondary objective of this study was to identify the demographics 
associated with the nonmedical use of benzodiazepines, specifically alprazolam, clonazepam, 
and diazepam.  The study also examined the correlation of other drugs of abuse with the 
nonmedical use of benzodiazepines.  The final objective of this study is to categorize the sources 
from which users obtained their first time supply of a benzodiazepine for a nonmedical purpose. 
2. Methods  
This retrospective cross-sectional study analyzes data acquired from the Social Networks among 
Appalachian People (SNAP) study.  SNAP is an ongoing longitudinal cohort study of social 
networks and HIV risk among rural Appalachian drug users who reside in Perry County, 
Kentucky. Perry County has a population of approximately 30,000 and is located in Southeastern 
5 
 
Kentucky.  The vast majority of the population is white (97%), with an average yearly household 
income of $33,000, and with 26% of individuals living in poverty.
7
  The SNAP study was 
approved by the Institutional Review Board (IRB) at the University of Kentucky. 
SNAP study participants were recruited using Respondent Driven Sampling (RDS) which has 
been effectively utilized in previous studies of hard to reach populations such as rural drug 
users.
8
  Initial recruits were identified via community outreach, word-of-mouth, and flyers.  
These initial recruits then solicited peers to participate in the study.  Subjects were monetarily 
reimbursed for successfully recruiting additional eligible study participants.  This process 
continued until the desired sample size was attained (n=503).  
Trained non-clinician researchers conducted baseline interviews and used the Addiction Severity 
Index (ASI)
9
 to determine illicit and prescription drug use.  Psychiatric disorders were diagnosed 
using the Mini-International Neuropsychiatric Interview (MINI), version 5.0.
10
  Demographic 
variables collected through completion of the ASI included age, gender, years of education, 
employment, financial status, health insurance status, health status, and a detailed history of both 
lifetime and past 30 day nonmedical substance use.  The MINI was used to evaluate if  
Diagnostic and Statistical Manual of Mental Disorders criteria were met for current major 
depressive disorder (MDD), generalized anxiety disorder (GAD), post-traumatic stress disorder 
(PTSD), and/or antisocial personality disorder (ASPD).  Additionally, participants were 
questioned regarding specific nonmedical drug sources (i.e., family member, friend, dealer).  
Participants were asked to provide specific drug names or street names in order to record lifetime 
and past 30 day use of substances for a nonmedical purpose (e.g., “to get high”).  The correct 
categorization of substances reported was confirmed before data analysis.  For the purposes of 
data analysis, only subjects that were categorized as using alprazolam, clonazepam, or diazepam 
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within the past 30 days were labeled as benzodiazepine users.  All data capable of identifying 
individual participants was purged before analysis.  The Institutional Review Board at the 
University of Kentucky granted an IRB exemption for this study. 
Subjects were divided into two groups, “past 30 day users of benzodiazepines” and “past 30 day 
non-users”, and the descriptive statistics were reported via a univariate analysis.  The Chi-square 
test, Fisher’s Exact test, and the Mann-Whitney rank-sum test for categorical and continuous 
variables were utilized to compare the demographic and substance abuse characteristics of each 
group respectively.  The chi-square test was utilized to identify significant (p<0.05) differences 
in the prevalence of MDD, GAD, PTSD, and ASPD between recent benzodiazepine users and 
non-users.  Finally, independent correlates of past 30 day benzodiazepine use were determined 
using a step-wise multiple logistic regression with an adjusted odds ratio (AOR) and 95% 
confidence intervals (CI) reported for each variable.  SPSS, version 20, was utilized for all 
analyses. 
3. Results 
503 participants were included in the study analysis.  The majority of participants were male 
(57%, n=206), white (94%, n=473), and had at least a high school education (56%, n=284).  The 
median age of participants was 33 years (interquartile range: 26 to 38 years).  All participants 
reported a history of nonmedical prescription opioid use, and 98% (n=493) reported past 30 day 
use.   
Table 1 displays the baseline characteristics among those who did (n=355) and did not (n=148) 
report any past 30 day use of alprazolam, clonazepam, or diazepam.  Median and interquartile 
range (IQR) of age and years of education completed did not significantly differ (p=0.2, p=0.8, 
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respectively) between those who had used benzodiazepines and those who had not.  However, 
benzodiazepine users did report a significantly greater (p=0.02) median of years of residence in 
Eastern Kentucky (n=30 years), than those who did not (n=27 years).  Benzodiazepine users 
were significantly more likely to describe themselves as religious (p=0.01) and non-white 
(p=0.02) as compared to non-users.  No significant differences in the socio-economic status were 
found among benzodiazepine users and non-users.  However, subjects who reported their self-
perceived health status as poor or fair had a 12.4% higher prevalence of benzodiazepine use 
(p=0.01).  Contrary to the results of perceived health status, the presence of chronic health 
conditions was not significantly different among benzodiazepine users and non-users (p=0.1).  
Additionally, there was no significant difference in the type of health insurance (i.e.., Medicaid, 
Medicare, private) used in terms of benzodiazepine users and non-users. 
Table 2 displays the univariate comparison of past 30 day substance use among benzodiazepine 
users and non-users.  The benzodiazepine group reported significantly higher rates of past 30 day 
use of several substances when compared to non-users.  Participants who reported past 30 day 
use of benzodiazepines were also 24% more likely to have illicitly used methadone (p<0.001),  
23.1% more likely to use oxycodone (p<0.001), 18.8% more likely to use marijuana (p<0.001), 
and 12.7% more likely to use alcohol (p=0.01).  The prevalence of reported past 30 day 
benzodiazepine use was very high with  71% (n=355) of participants reporting having used one 
or more benzodiazepines (i.e., alprazolam, clonazepam, or diazepam) at least once during the 
previous 30 day period.  88.5% (n=314) of participants who reported using benzodiazepines 
within the past 30 days reported using alprazolam.  Clonazepam was the second most commonly 
used benzodiazepine with 190 subjects (54%) reporting using the prescription drug for 
nonmedical purposes.  Diazepam, with 115 (32%) subjects reporting its use, was the least 
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commonly utilized benzodiazepine evaluated in this study. The majority of subjects reported 
using alprazolam only (n=119, 33.5%).  25.4% (n=90) subjects reported using both alprazolam 
and clonazepam, and 65 subjects (18.3%) reported using all three benzodiazepines (i.e., 
alprazolam, clonazepam, diazepam) evaluated in this study (Table 3).  As shown in Table 4, the 
most common primary source of benzodiazepines was from friends or family members (n=211, 
59%).  The next most common source was from a dealer (n=60, 17%).  Only 15% (n=53) of 
benzodiazepine users obtained their first prescription legitimately via a clinician such as a 
physician or dentist. 
A strong relationship between the nonmedical use of benzodiazepines and DSM-IV psychiatric 
disorders was found in this study (Table 5).  Participants that reported past 30 day use of 
alprazolam, clonazepam, and/or diazepam were found to have an 11.1% (p=0.01) higher 
prevalence of MDD versus benzodiazepine non-users.  Additionally, the prevalence of GAD was 
12.4% higher (p=0.005) in subjects who reported past 30 day benzodiazepine use.  Although 
6.6% more participants who reported recent benzodiazepine use met the criteria for a PTSD 
diagnosis, the relationship did not achieve statistical significance (p=0.053).  Finally, the rates of 
ASPD were nearly identical between benzodiazepine users and non-users, 31.5% versus 31.1% 
respectively (p=0.9). 
A logistic regression model (Table 6) was developed to identify independent correlates of recent 
benzodiazepine use.  After controlling for the possible confounding variables of age, sex, and 
race, the adjusted model revealed six variables associated with past 30 day benzodiazepine use.  
The strongest association was with illicit methadone use (AOR: 2.9, 95% CI: 1.9-4.6).  Other 
benzodiazepine abuse factors included marijuana use (AOR: 2.6, 95% CI: 1.6-4.01) and 
oxycodone use (AOR: 2.5, 95% CI: 1.6-3.97).  During the modeling process, substantial 
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collinearity between GAD and MDD was identified.  Although both disorders were associated 
with benzodiazepine use, a diagnosis of GAD via the MINI was the more significant factor of 
benzodiazepine use (AOR: 1.7, 95% CI: 1.01-2.77) in the final model.  A self-reported health 
status of poor or fair (AOR: 1.65, 95% CI: 1.05-2.6) as well as number of years a subject 
reported living in Appalachian, Kentucky (AOR: 1.03, 95% CI: 1.0-1.05) were also significant 
contributors to recent benzodiazepine use in the adjusted logistic model. 
4. Discussion 
The findings of this study are consistent with the hypothesis that nonmedical benzodiazepine use 
is strongly associated with major depressive disorder (MDD) and generalized anxiety disorder 
(GAD).    While other reports have described the common co-occurrence of psychiatric and 
substance use disorders
11
; this is the first study to suggest that people who abuse benzodiazepines 
are significantly more likely to have specific psychiatric disorders.    Therefore, future treatment 
and prevention programs must be developed to target both addiction and underlying psychiatric 
disorders.  Overall, 26% of participants were found to have MDD without regard to 
benzodiazepine use.  This rate is in agreement with recent literature that places the lifetime rate 
of developing a concurrent substance use disorder and MDD at 17.2%.
12
  The results of this 
study raise the question of potential self-medication among opioid drug abusers.  We found that 
those who met DSM-IV criteria for MDD or GAD were almost twice more likely to report 
nonmedical benzodiazepine use than those who did not. Considering benzodiazepines are 
indicated for the short term treatment of anxiety, benzodiazepine use was likely providing relief 
to an anxiety prone population of opioid drug abusers.  This study did not find a significant 
relationship between benzodiazepine use and PTSD.  While this result was plausibly due to the 
relatively small prevalence of PTSD among the study population; this finding was unexpected 
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due to a commonly held assumption regarding substance abuse as a coping mechanism utilized 
by individuals with PTSD.
13
   
It is expected that the high prevalence of psychiatric conditions in this study contributed to 
subjects self-perceived health status.  This study found poor health status was significantly 
associated with nonmedical use of benzodiazepines.  However, whether poor health was a factor 
promoting benzodiazepine use or if benzodiazepine use led to decreased health cannot be 
determined.  Of note, previous studies have found opioid users who co-abuse benzodiazepines 
experience higher substance dependence relapse rates and in general, poorer treatment 
outcomes.
14,15
  Therefore, an investment in overcoming health disparities may be needed to stem 
the epidemic of drug abuse. 
The large percentage of benzodiazepine users in this study is in accordance with existing 
literature which suggests that opioids and benzodiazepines are commonly abused in tandem for 
nonmedical purposes.  Several studies have evaluated the drug use history of patients entering 
methadone clinics for treatment of opioid dependence.  These studies found that anywhere 
between 18-54% of admitted patients required detoxification from benzodiazepines.
16,17,18
  
Alprazolam, which is the most commonly prescribed benzodiazepine nationally
19
, was also the 
most prevalent benzodiazepine reportedly used in this study of opioid drug users.   
The high prevalence of opioid and benzodiazepine co-use is concerning for several reasons.  
First, current practice guidelines do not support the long term use of benzodiazepines to treat 
anxiety.  Also, benzodiazepines have been shown to be of little benefit for patients suffering 
from chronic pain.
20
  Compounding these dangers, is the fact that many benzodiazepines increase 
opioid associated respiratory depression.  Additionally, the effectiveness of the opioid antagonist 
11 
 
naloxone is decreased in the presence of benzodiazepines thus potentially hampering the 
treatment of acute overdoses.  Statistics regarding acute overdose were not collected in this 
study, but opioids and benzodiazepines are reportedly the most common prescription drugs 
involved in these types of clinical scernarios.
21
   
Benzodiazepines have been shown to increase the rewarding and reinforcing effects of opioids 
which potentiates further abuse and dependence.
22
 Of note is the strong association between 
nonmedical use of benzodiazepines and illicit methadone and oxycodone use found in this study.  
This finding is consistent with literature that found drug users will augment the effects of 
oxycodone with benzodiazepines to increase their “high.”
23  
This observation is supported by 
pharmacokinetic studies that found that diazepam increased the concentration of methadone in 
the central nervous system.
24
  Interestingly, this association was not noted in subjects reporting 
the use of Oxycontin®.   Since Oxycontin® is a potent long acting formulation of oxycodone, 
this suggests opioid abusers may be utilizing benzodiazepines to intensify the effects of less 
potent narcotics.   
Residents of Appalachia are often self-sufficient and distrustful of the healthcare system.
25,26 
 
These traits give credence to the hypothesis of practicing self-medication to treat  psychiatric 
disorders.  This study found that the odds of using a benzodiazepine increase by 3% each 
additional year living in Eastern Kentucky, which suggests that as immersion in Appalachian 
culture increases, the likelihood of seeking professional treatment decreases.  It is possible many 
participants were hesitant to seek professional assistance because of the stigma associated with 
psychiatric disorders.  This study found that more than half of recent benzodiazepine users 
obtained their supply from friends or family members.  These findings are consistent with a 2012 
national study by McCabe et al. which reported that 55% of teenage subjects reporting 
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nonmedical use of opioids acquired them from friends or family.
27
 Since the diversion of 
prescription pharmaceuticals is a contributing factor in over half of all fatal drug overdoses
28
, an 
investment in campaigns that educate the public regarding the dangers of sharing prescription 
drugs appears to be warranted especially in this rural population.   
The main limitation of this study is its cross-sectional design which does not allow for causality 
to be established.  A further limitation of this study is that no measure of degree of 
benzodiazepine abuse or dependence was collected.  Due to the constraint of using secondary 
data, only participants reporting the use of alprazolam, clonazepam, or diazepam were classified 
as benzodiazepine users.  Therefore, it is possible a subject may have been mistakenly classified 
as a benzodiazepine non-user when in fact they used another agent of the class.  However, since 
most participants reported using more than one benzodiazepine, this limitation likely had little 
impact on final results.  Lastly, since the study population consisted of rural opioid users living 
in only one county of Kentucky, the results of this study may not be generalizable to all opioid 
users. 
Despite these limitations, this study suggests nonmedical benzodiazepine use is associated with 
psychiatric disorders and reinforces the fact that nonmedical use of prescription drugs is a multi-
faceted problem. The results of this study reinforce the need for intervention at both the 
individual and community level.  High rates of MDD and GAD were found among this cohort of 
opioid drug abusers living in medically underserved region of Appalachian, Kentucky.  The 
association of MDD and GAD with benzodiazepine use suggests subjects were possibly self-
treating their conditions by escalating their degree of prescription drug abuse to include 
benzodiazepines.  A lack of accessible mental healthcare providers may be a contributing factor 
to the high rates of nonmedical benzodiazepine use found in this study.  An additional 
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contributing factor may be that people suffering from mood disorders fear exclusion in these 
typically clannish communities.  If this is the case, further development of mental health 
outreach programs and access to healthcare services may reduce the abuse of benzodiazepines in 
Appalachian Kentucky.    In 2012, the Kentucky legislature passed House Bill 1 in an attempt to 
improve prescription oversight of controlled substances.  This legislation imposes regulations 
concerning pain clinics, improved guidelines for the prescribing of controlled substances, and 
requires the mandatory utilization of an electronic prescription drug monitoring program (e.g, 
KASPER [Kentucky All Schedule Prescription Electronic Reporting]).  Longitudinal studies are 
needed to determine the effect of prescription drug monitoring programs (e.g., KASPER) on the 
accessibility of benzodiazepines.  By limiting accessibility of these drugs, users may seek out the 
psychiatric treatment they require instead of attempting to self-medicate by using 
benzodiazepines and other drugs of abuse.  However, due to the strong association of 
prescription drug abuse and psychiatric disorders, the provision of mental healthcare must be of 
utmost importance in order to stem the tide of drug abuse in Appalachian Kentucky.  
 
 
 
 
 
 
 
14 
 
References 
1. Substance Abuse and Mental Health Services Administration, Results from the 2011 National 
Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS 
Publication No. (SMA) 12-4713. Rockville, MD: Substance Abuse and Mental Health Services 
Administration, 2012. 
2. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical 
use of prescription opioids. Clin J Pain 2011;27:194–202. 
3. Verispan LLC. Vector One National, Years 1998-2007, extracted July 2008 [cited by Belouin 
SJ, Reuter N, Borders-Hemphill V, Mehta H. Prescribing trends for opioids, benzodiazepines, 
amphetamines, and barbiturates from 1998-2007. Rockville, MD: Drug Testing Advisory Board, 
Substance Abuse and Mental Health Services Administration; August 2008. 
http://nac.samhsa.gov/dtab/presentations/aug08/seanbelouindtab0808_508.pdf. Accessed March 
12, 2013. 
4. U.S. Drug Enforcement Administration. Office of Diversion Control. Automation of Reports 
and Consolidated Orders System (ARCOS). Available at: 
http://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html. Accessed March 29, 
2013 
5. Zhang, Z., Infante, A. , Meit, M., & English, N. (2008 ). An Analysis of Mental Health and 
Substance Abuse Disparities & Access to Treatment Services in the Appalachian Region. 
Retrieved March, 2013 from the Appalachian Regional Commission Online Resource Center 
Web site: http://www.arc.gov/research/researchreportdetails.asp?REPORT_ID=71 
6. Khantzian EJ: The self-medication hypothesis of addictive disorders: focus on heroin and 
cocaine dependence. Am J Psychiatry 1985, 142:1259-1264. 
7.  U.S. Census Bureau; American FactFinder Web site.  http://factfinder2.census.gov. Accessed 
March 1, 2013. 
8. Young AM, Havens JR, Leukefeld CG. 2012. A comparison of rural and urban nonmedical 
prescription opioid users’ lifetime and recent drug use. Am J Drug Alcohol Abuse 38:220–227. 
9. McLellan, A.T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, 
H., Argeriou, M., 1992. The fifth edition of the Addiction Severity Index. J. Subst. 
Abuse Treat. 9, 199–213. 
10. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, 
T., Baker, R., Dunbar, G.C., 1998. The Mini-International Neuropsychiatric 
Interview (M.I.N.I.): the development and validation of a structured diagnostic 
psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (Suppl.), 
22–33. 
15 
 
11. Hasin DS, Goodwin RD, Stinson FS, Grant BF: Epidemiology of major depressive disorder: 
results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch 
Gen Psychiatry 2005: 62:1097-116. 
12. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and 
comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.  
Arch Gen Psychiatry 2005; 62:617-627. 
13. Waldrop AE, Back SE, Verduin ML, Brady KT. Triggers for cocaine and alcohol use in the 
presence and absence of posttraumatic stress disorder. Addict Behav. 2007;32:634–9.  
14. Compton WM, Cottler LB, Abdallah AB, et al. Substance dependence and other psychiatric 
disorders among drug dependent subjects: race and gender correlates. Am J Addict 2000; 9:113-
125. 
15. Hasin D, Liu X, Nunes E, et al. Effects of major depression on remission and relapse of 
substance dependence.  Arch Gen Psychiatry 2002; 59:375-380. 
16. Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M.  Characteristics of benzodiazepine 
abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli 
clinic. Drug Alcohol Depnd. 1999; 55,63-68. 
17. Rooney S, Kelly G, Bamford L, Sloan D, O’Connor JJ. Co-abuse of opiates and 
benzodiazepines. Irish J. Psychol. Med. 1999: 168:36-41. 
18. Specka M, Bonnet U, Heilmann M, Schifano F, Scherbaum N. Longitudinal patterns of 
benzodiazepine consumption in a German cohort of methadone maintenance treatment patients. 
Hum. Psychopharmacol. 2011; 26:404-411. 
19.  Theodorou A, Johnson K, Slezak J, Szychowski J. Recent trends in utilization of antianxiety 
medication.  Am J Pharm Benefits. 2009; 1: 225-229. 
20. King SA, Strain JJ. Benzodiazepine use by chronic pain patients. Clin. J. Pain. 1990; 6:143-
147. 
21. Xiang Y, Zhao W, Xiang H, Smith GA.  ED visits for drug-related poisoning in the United 
States, 2007. Am. J. Merg. Med. 2012; 30:293-301. 
22. Walker, Bm, Ettenberg A. Benzodiazepine modulation of opiate reward. Exp. Clin. 
Psychopharmacol. 2001; 9:191-197. 
23. Spiga R, Huang DB, Meisch RA, Graboski J. Human methadone self-administration: effects 
of diazepam pretreatment. Exp. Clin. Psychopharmacol. 2001; 9:40-46. 
24. Shah NS, Patel VO, Donald AG. Effect of diazepam, desmethylimipramine, and SKF 525-A 
on the disposition of levo-methadone in mice after single or double injections. Drug Metab. 
Dispos. 1979; 7:241-242. 
25. Smith, SL & Tessaro, IA. Cultural perspectives on diabetes in an Appalachian population. 
American Journal of Health Behavior. 2005; 29: 291-301. 
16 
 
26. Hatcher J, Dignan M, Schoenberg N. How do rural health care providers and patients view 
barriers to colorectal screening? Insights from Appalachian Kentucky. The Nursing Clinics of 
North America. 2011; 46:181-92. 
27. Leftover Prescription Opioids and Nonmedical Use Among High School Seniors: A Multi-
Cohort National Study. 
28. Hall A. J., Logan J. E., Toblin R. L., Kaplan J. A., Kraner J. C., Bixler D. et al. Patterns of 
abuse among unintentional overdose fatalities. JAMA 2008; 300: 2613–20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
Table 1. Demographic data
 
 
Demographics Benzo Use 
30 d 
(n=355) 
No Benzo Use 
30 d 
(n=148) 
 Total 
(n=503) 
 n % n % P n % 
Median age (IQR) 33 (26-38) 32 (25-36) 0.153 33 (26-38) 
Median years lived in 
Eastern Kentucky 
(IQR) 
29 (24-35) 27 (22-33) 0.015 28 (23-25) 
 Median years of 
education completed 
(IQR) 
11 (10-12) 11 (10-12) 0.841 11(10-12) 
Male gender 194 54.6 92 62.2 0.121 286 56.9 
Religious 112 31.5 29 19.6 0.007 141 28.0 
Caucasian 329 92.7 145 98.0 0.020 474 94.2 
Employment  
Full-time 114 32.1 59 39.9 0.095 173 34.4 
Part-time 90 25.4 26 17.5 0.059 116 23.1 
Disabled 48 13.5 19 12.8 0.837 67 13.3 
Student/service/military 6 1.7 2 1.4 1.00 8 1.6 
Controlled 
environment 
2 1.4 6 1.7 .0096 8 1.6 
Unemployed 95 26.8 36 24.3 0.57 131 26.0 
Pension for physical 
disability 
41 11.5 20 13.5 0.539 61 12.1 
Someone contributes 
majority of support 
143 40.3 47 31.8 0.072 190 37.8 
Health insurance status    
Medicaid/Medicare 108 30.4 44 29.7 0.877 152 30.2 
Private 14 3.9 4 2.7 0.606 18 3.6 
Uninsured 233 65.6 100 67.6 0.676 333 66.2 
Self-reported health 
status 
 
Poor/fair 178 50.2 56 37.8 0.012 234 46.5 
Good 126 35.5 67 45.3 0.051 193 38.4 
Very good/excellent 51 14.3 25 16.9 0.471 76 15.1 
Chronic health 
condition(s) 
131 36.9 44 29.7 0.124 175 34.8 
Ever treated for drug 
abuse 
177 49.9 79 53.4 0.472 256 50.9 
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Table 2. Prevalence of psychiatric disorders and substance abuse 
Psychiatric 
disorders 
Benzo Use 
30 d 
(n=355) 
No Benzo Use 
30 d 
(n=148) 
 Total 
(n=503) 
n % n % P n % 
MDD 104 29.3 27 18.2 0.01 131 26.0 
GAD 116 32.7 30 20.3 0.005 146 29.0 
PTSD 57 16.1 14 9.5 0.053 71 14.1 
ASPD 112 31.5 46 31.1 0.918 158 31.4 
Substance use    
(30 day) 
 
Any opioid 352 99.2 141 95.3 0.009 493 98.0 
Alcohol 208 58.6 68 45.9 0.009 276 54.9 
Heroin 14 3.9 8 5.4 0.465 22 4.4 
Illicit methadone 241 67.9 65 43.9 0.000 306 60.8 
Licit methadone 12 3.4 2 1.4 0.207 14 2.8 
Oxycodone ER 252 71.0 99 66.9 0.362 351 69.8 
Oxycodone 281 79.2 83 56.1 0.000 364 72.4 
Crack 45 12.7 12 8.1 0.141 57 11.3 
Cocaine 88 24.8 25 16.9 0.053 113 22.5 
Methamphetamine 14 3.9 3 2.0 0.278 17 3.4 
Marijuana 237 66.8 71 48 0.000 285 56.7 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
Table 3. Detailed analysis of benzodiazepine use (n=355) 
Self-reported benzodiazepine use 
 n % 
Alprazolam alone 119 33.5 
Clonazepam and alprazolam 90 25.4 
Alprazolam, clonazepam, 
diazepam  
65 18.3 
Diazepam and alprazolam 40 11.3 
Clonazepam alone 31 8.7 
Diazepam alone 6 1.7 
Clonazepam and diazepam 4 1.1 
Total 355 100 
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Table 4. Sources of benzodiazepines 
Source first time used benzodiazepine  
 n % 
Spouse 16 4.5 
Family 57 16.1 
Friends 138 38.9 
Physician/Dentist 52 14.6 
Dealer 60 16.9 
Stolen 17 4.8 
Multiple sources 1 0.3 
No response 14 3.9 
Total 355 100 
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Table 5. Association between benzodiazepine use and psychiatric disorders 
Association between benzodiazepine use and psychiatric disorders 
 MDD GAD PTSD 
 Odds 
Ratio 
95% CI P 
Odds 
Ratio 
95% CI P 
Odds 
Ratio 
95% 
CI 
P 
Alprazolam 
alone 
1.250 
0.791-
1.974 
0.338 0.871 
0.550-
1.381 
0.557 0.845 
0.459-
1.556 
0.588 
Clonazepam 
alone 
0.528 
0.198-
1.405 
0.194 0.569 
0228-
1.418 
0.221 0.403 
0.094-
1.727 
0.289 
Diazepam 
alone 
5.827 
1.05-
32.194 
0.042 0.486 
0.056-
4.192 
0.677 1.220 
0.140-
10.598 
0.601 
Clonazepam 
and 
diazepam 
8.695 
0.896-
84.340 
0.056 0.814 
0.084-
7.888 
1.000 2.043 
0.210-
19.917 
0.457 
Clonazepam 
and 
alprazolam 
1.192 
0.718-
1.978 
0.497 1.537 
0.951-
2.484 
0.078 1.151 
0.610-
2.171 
0.665 
Diazepam 
and 
alprazolam 
0.942 
0.447-
1.985 
0.875 1.350 
0.684-
2.666 
0.386 2.548 
1.209-
5.367 
0.011 
Alprazolam, 
clonazepam, 
diazepam  
1.423 
0.811-
2.499 
0.218 
 
2.210 
1.297-
3.766 
0.003 1.638 
0.840-
3.193 
0.144 
Total 
1.857 
1.154-
2.988 
0.010 1.909 
1.208-
3.018 
0.005 1.831 
0.986-
3.400 
0.053 
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Table 6. Independent factors of past 30 day benzodiazepine use 
Factors of benzodiazepine use in opioid drug abusers 
 Odds Ratio Adjusted Odds Ratio
* 
95% CI 
Illicit methadone 2.755 2.944 1.902-4.557 
Marijuana 2.264 2.565 1.640-4.013 
Oxycodone  2.463 2.521 1.602-3.968 
GAD 1.736 1.669 1.005-2.770 
Poor/Fair health 1.751 1.652 1.049-2.600 
Time lived in eastern 
KY 
1.027 1.028 1.004-1.052 
*controlling for age, sex, race 
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Figure 1. Self-reported benzodiazepine use 
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Figure 2. Association of benzodiazepine use with psychiatric disorders 
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Figure 3. Forest plot of factors of benzodiazepine use 
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Figure 4. Sources of benzodiazepines 
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